Abstract: In an image guidance method, a stream of cone-beam computed tomography (CBCT) images of an anatomical organ is acquired using a CBCT imaging device (34). For each CBCT image (44), the surface of the organ in the CBCT image is segmented to generate a segmented surface (70) of the anatomical organ in the CBCT image. Occluded shape reconstruction (66) using a statistical shape prior (68) may be used to reconstruct a missing or occluded surface portion. A pre-operative medical image (12) of the anatomical organ and the CBCT image are spatially registered by warping one of the images to the other of the images using point set registration of a segmented surface (30) of the organ in the preoperative medical image and the segmented surface of the organ in the CBCT image. A fused image (82) is displayed that combines the warped image and the other image.

Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.

Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.

Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.

Abstract: The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

Abstract: In an image guidance method, a stream of cone-beam computed tomography (CBCT) images of an anatomical organ is acquire using a CBCT imaging device (34). For each CBCT image (44), the surface of the organ in the CBCT image is segmented to generate a segmented surface (70) of the anatomical organ in the CBCT image. Occluded shape reconstruction (66) using a statistical shape prior (68) may be used to reconstruct a missing or occluded surface portion. A pre-operative medical image (12) of the anatomical organ and the CBCT image are spatially registered by warping one of the images to the other of the images using point set registration of a segmented surface (30) of the organ in the preoperative medical image and the segmented surface of the organ in the CBCT image. A fused image (82) is displayed that combines the warped image and the other image.

Abstract: The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.

Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.

Abstract: The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

Abstract: A system for transcatheter arterial chemoembolization (TACE) includes a visualization software module (115) configured to assess vascular geometry of an organ in an image of the organ. A tumor viability software module (124) is configured to provide a tumor viability map of the organ to be overlaid on the image of the organ. An imaging modality (126) is configured to track an instrument in or in proximity of the organ to ensure that the instrument is positioned within the organ for treatment in accordance with the tumor viability map.

Abstract: The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

Abstract: The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.

Abstract: The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

Abstract: The present invention provides methods for preventing or treating infections, especially bacterial infections, by administering selective inhibitors of ATP production to inhibit glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As such, the present invention further provides methods for preventing or treating inflammation and sepsis associated with infections, as well as increased wound healing and decreased wound scarring.

Abstract: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention.

Abstract: The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity.

Abstract: The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.